Answers are grounded in this paper and cite their sources.
Purpose Colorectal cancer (CRC) survivors experience persistent challenges that negatively affect health-related quality of life (HRQoL). While mobile health (mHealth) may offer a useful approach to survivorship care, limited user involvement and scarcity of structured programs in developing countries remain barriers. This study aimed to co-design and evaluate the feasibility of an mHealth survivorship program for CRC survivors following primary treatment. Methods A mixed-methods study was conducted in two phases. Phase 1 utilized a user-centered design framework involving 12 co-designers across nine online sessions to develop and refine the FORYOU mHealth program. Phase 2 was a pilot randomized controlled trial (RCT) with 30 CRC survivors to assess feasibility and preliminary effectiveness of the 12-week program, measured by HRQoL outcomes. Results In phase 1, the co-designed program indicated above-average usability (System Usability Scale ≥ 68) and adequate acceptability (E-Acceptability Scale ≥ 24). In phase 2, the adherence rate was 73.3%; participants in the intervention group completed an average of 5.4 out of 6 sessions and accessed the app 9.7 times. Although no significant between-group difference was observed in overall HRQoL, exploratory findings were mixed. The intervention favored the subscale functional well-being ( P < 0.05; g = 1.34), whereas the control group favored the secondary outcome, fatigue. These preliminary findings require cautious interpretation. Conclusion The co-designed mHealth program was usable and acceptable, and the pilot RCT was feasible among CRC survivors after primary treatment. Exploratory findings suggested possible benefits in selected outcomes, but these preliminary findings require confirmation in a larger adequately powered trial. Implications for Cancer Survivors This co-designed mHealth survivorship program showed encouraging engagement among CRC survivors after primary treatment, with exploratory findings suggesting potential effects on selected survivorship outcomes. Trial registration NCT07158671 on ClinicalTrials.gov.
No takes yet. Share an insight, caveat, or question.
Do et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: